Fol­low­ing foot­steps of chart-top­ping Chi­nese coun­ter­parts, Al­pham­ab On­col­o­gy files IPO at HKEX

8 hours ago
China
IPOs

Seer en­tices ex FDA com­mis­sion­er Mc­Clel­lan to its board; Van­da tests tradip­i­tant in mo­tion sick­ness study

8 hours ago
Protocols

UP­DAT­ED: With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

9 hours ago
Regulatory

The $1.1M good­bye: Gilead CSO John McHutchi­son is out as Daniel O’Day shakes up the se­nior team

9 hours ago
People

Bay­er, Long­wood back star re­searcher's deep dive in­to the tu­mor mi­croen­vi­ron­ment for new I/O tar­gets

9 hours ago
Startups
Venture

Who’s the tough­est on drug prices? A game of po­lit­i­cal one-up­man­ship is dri­ving the pol­i­cy de­bate in Wash­ing­ton

9 hours ago
Bioregnum

FDA warns Strides Phar­ma for un­con­trolled doc­u­ment shred­ding

10 hours ago
Regulatory

In­ovio ax­es staff, chops R&D pro­grams in chase for elu­sive com­mer­cial win — though there's still a lot on their plate

11 hours ago
People

Go­ing in­side cells, Sung Joo Lee has sketched some big goals for his small — but glob­al — team of drug hunters

11 hours ago
R&D
Startups

Astel­las buys in­to Fre­quen­cy's re­gen­er­a­tive med strat­e­gy with a $625M al­liance on hear­ing loss

11 hours ago
Deals

UP­DAT­ED: Mallinck­rodt forced to shut­ter ALS study test­ing its con­tro­ver­sial Ac­thar gel

11 hours ago
R&D

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

Yesterday
Deals

AI-fo­cused No­table Labs score $40M in fund­ing; Seat­tle Ge­net­ics/Astel­las sub­mit mar­ket­ing ap­pli­ca­tion for en­for­tum­ab ve­dotin

Yesterday
Protocols

Roche's Genen­tech goes on deal spree, un­veil­ing third deal on the same day

Yesterday
Deals

UP­DAT­ED: As ri­vals march on, No­var­tis se­cures pri­or­i­ty FDA re­view for sick­le cell dis­ease ther­a­py

Yesterday
R&D
Regulatory

Keen to stay out front in cell ther­a­py, Gilead­'s Kite builds its own vi­ral vec­tor man­u­fac­tur­ing op­er­a­tions

Yesterday
Cell/Gene Tx

Part club, part guide, part land­lord: Arie Bellde­grun is blue­print­ing a string of be­spoke biotech com­plex­es in glob­al boom­towns — start­ing with Boston

Yesterday
People
Venture

Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

Yesterday
Deals
Discovery

San Diego oph­thalmic biotech up­start rais­es $28M on al­ter­na­tive to corneal trans­plant

Yesterday
Startups
Venture

Deal hun­gry So­sei Hep­tares brings Roche's Genen­tech on board as a part­ner

Yesterday
Deals

AM-Phar­ma gath­ers €116M for PhI­II pro­gram on kid­ney drug Pfiz­er passed on

Yesterday
Venture

Takeda's trans­la­tion­al cell ther­a­py group revs up for a race to the clin­ic with off-the-shelf CAR-T

Yesterday
Cell/Gene Tx
People

Mi­cro­cap Capri­cor soars on in­ter­im PhII DMD da­ta show­ing func­tion­al ben­e­fit for old­er pa­tients

2 days ago
Cell/Gene Tx
R&D

Alk­er­mes adds bipo­lar I dis­or­der to its FDA wish­list; Con­go con­firms first Ebo­la case in large city

2 days ago
Protocols
1234 Next page Last page